REFERENCES
- Pennell DJ. T2* Magnetic resonance and myocardial iron in thalassemia. Ann NY Acad Sci. 2005;1054:373–378.
- Ha SY, Mok AS, Chu WC, . A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*. Hemoglobin. 2009;33(5):323–331.
- Telfer PT, Prescott E, Holden S, . Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110(4):971–977.
- Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1–2):41–47.
- Tanner MA, Galanello R, Dessi C, . Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10(1):12.
- Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in β-thalassemia. Hemoglobin. 2008;32(1–2):29–34.
- Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol. 2010;85(5):430–438.
- Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466–475.